ScholarLens Back to search
2009•Leukemia & lymphoma/Leukemia and lymphomaRequires access

Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide±rituximab

Heather E. Eve, John Francis Seymour, Simon A. Rule

Open publisher page 16 citations

Abstract

Mantle-cell lymphoma (MCL) remains an incurable disease with a median survival of 3–5 years and no widely agreed approach to its initial management. Fludarabine as a single agent achieves response ...

About this research paper

What this paper is about

Mantle-cell lymphoma (MCL) remains an incurable disease with a median survival of 3–5 years and no widely agreed approach to its initial management. Fludarabine as a single agent achieves response ...

Why it matters

OpenAlex reports 16 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Mantle-cell lymphoma (MCL) remains an incurable disease with a median survival of 3–5 years and no widely agreed approach to its initial management. Fludarabine as a single agent achieves response ...

Key concepts: Fludarabine, Mantle cell lymphoma, Rituximab, Medicine, Cyclophosphamide, Oncology, Lymphoma, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide±rituximab — Research Paper | ScholarLens